RIG-3 is a glycosylphosphatidylinositol (GPI)-anchored protein expressed in neurons. Key features include:
Domain structure: Immunoglobulin (Ig) domains and fibronectin type III (FNIII) repeats.
Function: Modulates acetylcholine receptor (AChR) clustering at neuromuscular junctions (NMJs) and regulates Wnt signaling via interactions with CAM-1, a Ror-type receptor tyrosine kinase .
Aldicarb hypersensitivity: rig-3 mutants exhibit heightened sensitivity to aldicarb, a cholinesterase inhibitor, due to increased AChR density at NMJs .
Post-synaptic potentiation: RIG-3 loss amplifies endogenous excitatory postsynaptic currents (EPSCs) and exogenous ACh-activated currents in body-wall muscles .
CAM-1 inhibition: RIG-3 binds CAM-1 to suppress Wnt ligand activity, maintaining neuronal polarity and synaptic stability .
Phenotypic rescue: Expression of RIG-3 in cholinergic neurons restores normal aldicarb sensitivity and AChR levels in mutants .
Though not commercially available, custom antibodies have been critical in:
Localization studies: Immunostaining confirmed RIG-3 expression in C. elegans motor neurons and ALM mechanosensory neurons .
Functional assays: Antibodies validated RIG-3’s GPI anchoring and its role in ribosome assembly during Nf-κb1 mRNA translation .
| Parameter | Wild Type | rig-3 Mutant |
|---|---|---|
| Aldicarb sensitivity | Normal | Hypersensitive |
| Muscle AChR density | Baseline | Increased |
| Neuronal polarity defects | Absent | Present |
| Wnt signaling activity | Regulated | Hyperactive |
While RIG-3 is not directly conserved in mammals, its regulatory mechanisms offer insights into:
Neurodegenerative diseases: Dysregulated synaptic plasticity in Alzheimer’s and Parkinson’s .
Cancer metastasis: Wnt signaling pathways targeted by RIG-3 homologs .